Join our daily newsletter At The Bell to receive exclusive market insights
4DMedical Ltd (ASX:4DX) has signed a major commercial contract with Queensland-based diagnostic imaging services provider Qscan Radiology Clinics relating to the former’s lung health assessment products.
The agreement follows a successful pilot of 4DMedical’s products with the latter and will be the first commercial contract in Australia to include products from the Pulmonary Function and Pulmonary Structure suites.
A key inclusion will be CT LVAS (Computed Tomography Lung Ventilation Analysis Software), which allows for in-depth analysis of functional lung health from CT scans.
Qscan is one of Australia’s top providers of medical imaging, with 40 clinics in Queensland, New South Wales, ACT, Tasmania, and Western Australia. According to its commercial agreement with 4DMedical, the whole suite of ‘respiratory imaging solutions’ will be available at a range of practices in Brisbane.
4DMedical founder, managing director, and CEO Andreas Fouras said he was pleased to see the company reach a commercial agreement after a successful pilot.
“This partnership ensures that more patients and clinicians have access to detailed, actionable insights into lung health, supporting better healthcare outcomes,” Mr Fouras said.
“Momentum continues to build with the commercialisation of our technology across the US and Australia. With the addition of Qscan to our network of providers in Australia, I am excited to see our footprint expand to ensure our cutting-edge technology is now becoming more readily available to all Australians.”
4DMedical shares have moved up 6.19% after the news to sell at 60c each.
Join the discussion: See what HotCopper users are saying about 4DMedical Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
